1832 Asset Management L.P. Vertex Pharmaceuticals Inc Transaction History

1832 Asset Management L.P.

$55.8 Billion
Q3 2024

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$392.81 - $485.53 $451,731 - $558,359	-1,150 Reduced 19.9%	4,630 $2.17 Million
Q1 2024 May 14, 2024	SELL	$407.69 - $446.08 $208,737 - $228,392	-512 Reduced 8.14%	5,780 $2.42 Million
Q4 2023 Feb 13, 2024	BUY	$343.0 - $410.68 $264,110 - $316,223	770 Added 13.94%	6,292 $2.56 Million
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $1.87 Million - $2 Million	5,522 New	5,522 $1.92 Million
Q2 2023 Aug 11, 2023	SELL	$314.42 - $351.91 $504,958 - $565,167	-1,606 Reduced 25.52%	4,688 $1.65 Million
Q1 2023 May 12, 2023	SELL	$283.23 - $323.1 $337,043 - $384,489	-1,190 Reduced 15.9%	6,294 $1.98 Million
Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $11.8 Million - $13.3 Million	-41,441 Reduced 84.7%	7,484 $2.16 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $64,623 - $72,105	236 Added 0.48%	48,925 $14.2 Million
Q2 2022 Aug 15, 2022	BUY	$234.96 - $292.55 $11.4 Million - $14.2 Million	48,689 New	48,689 $13.7 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $0 - $0	0 Closed	0 $0
Q4 2021 Feb 15, 2022	SELL	$177.01 - $223.45 $14.9 Million - $18.8 Million	-84,040 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$181.39 - $202.99 $10.4 Million - $11.6 Million	-57,165 Reduced 40.48%	84,040 $15.4 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $23.7 Million - $27.9 Million	126,205 Added 841.37%	141,205 $27.4 Million
Q1 2021 May 17, 2021	SELL	$207.02 - $241.31 $7.31 Million - $8.52 Million	-35,300 Reduced 70.18%	15,000 $3.21 Million
Q4 2020 Feb 16, 2021	SELL	$207.01 - $276.09 $150 Million - $200 Million	-724,100 Reduced 93.5%	50,300 $11.7 Million
Q3 2020 Nov 16, 2020	SELL	$255.65 - $303.1 $74.2 Million - $88 Million	-290,200 Reduced 27.26%	774,400 $209 Million
Q2 2020 Aug 14, 2020	BUY	$225.48 - $295.8 $12.3 Million - $16.2 Million	54,700 Added 5.42%	1,064,600 $304 Million
Q1 2020 May 26, 2020	BUY	$199.77 - $247.81 $202 Million - $250 Million	1,009,500 Added 252375.0%	1,009,900 $233 Million
Q1 2020 May 14, 2020	SELL	$199.77 - $247.81 $135 Million - $167 Million	-675,600 Reduced 99.94%	400 $96,000
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $79.6 Million - $107 Million	477,600 Added 240.73%	676,000 $147 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $27.3 Million - $30.7 Million	164,200 Added 480.12%	198,400 $32.4 Million
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $28.5 Million - $33 Million	-173,300 Reduced 83.52%	34,200 $6.12 Million
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $80.6 Million - $95.8 Million	-492,100 Reduced 70.34%	207,500 $36.8 Million
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $31.1 Million - $39.4 Million	-204,925 Reduced 22.66%	699,600 $114 Million
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $119 Million - $136 Million	708,025 Added 360.32%	904,525 $172 Million
Q2 2018 Aug 14, 2018	SELL	$145.72 - $169.96 $120 Million - $140 Million	-824,000 Reduced 80.74%	196,500 $32.6 Million
Q1 2018 May 15, 2018	BUY	$151.6 - $177.13 $5.97 Million - $6.98 Million	39,400 Added 4.02%	1,020,500 $165 Million
Q4 2017 Feb 14, 2018	BUY	$137.28 - $155.55 $9.66 Million - $11 Million	70,398 Added 7.73%	981,100 $145 Million
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $135 Million - $148 Million	910,702	910,702 $133 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

Capital World Investors Los Angeles, CA

26.8M
Shares

$12.5 Billion
1.99% of portfolio
Vanguard Group Inc Valley Forge, PA

23.2M
Shares

$10.8 Billion
0.2% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$9.9 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.8M
Shares

$5.49 Billion
0.23% of portfolio
Capital Research Global Investors Los Angeles, CA

9M
Shares

$4.18 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of 1832 Asset Management L.P., based on Form 13F filings with the SEC.

News

Stay updated on 1832 Asset Management L.P. with notifications on news.

Account